* Line results from phase 3 Kyprolis (Carfilzomib) clarion
study in newly diagnosed multiple myeloma patients
The post BRIEF-Amgen says phase 3 study of Carfilzomib did not meet primary endpoint appeared first on NASDAQ.
BRIEF-Amgen says phase 3 study of Carfilzomib did not meet primary endpoint
